CARDIMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Other Events, Financial Statements and Exhibits
Item 8.01 Other Events
On May 19, 2006, the U.S. Food and Drug Administration granted 510(k) marketing clearance for the Cardima Ablation System, which ablates cardiac tissue during heart surgery using radio frequency (RF) energy. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
- Financial statements of business acquired.
- Pro forma financial information.
- Exhibits.
99.1 Press Release of Cardima, Inc. dated May 25, 2006
Contact:
Cardima, Inc.
Gabriel B. Vegh
510-354-0300
http://www.cardima.com/
Source: Cardima, Inc.